BMY

Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace o

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% po

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...